PMID- 2115613
OWN - NLM
STAT- MEDLINE
DCOM- 19900828
LR  - 20130304
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 4
IP  - 7
DP  - 1990 Jul
TI  - Recombinant gamma-interferon as first line therapy for high risk myelodysplastic 
      syndromes. Italian MDS Study Group.
PG  - 480-5
AB  - Thirty patients affected by previously untreated high risk myelodysplastic 
      syndromes (MDS) were treated with human recombinant gamma-interferon 
      (r-IFN-gamma): 15 of them with a higher dose (HD) of 0.1 mg/sqm, three times a 
      week and 15 with a lower dose (LD) of 0.01 mg/sqm, three times a week, both doses 
      administered subcutaneously (s.c.). The therapy was fairly well tolerated and few 
      major toxic events were documented. Sustained improvement of one or more 
      clinico-hematologic parameters was observed in 43.3% of the patients (26.6% and 
      60.0% for the lower and higher dose, respectively). Median survival time from the 
      start of IFN-gamma therapy was 15+ months (range: 1-26) for patients with 
      refractory anemia with excess of blasts (RAEB) versus 5 months (range 2-12) for 
      patients with RAEB in transformation (RAEB-t); 15+ months (range 1-26) for HD 
      patients versus 8 months (range 2-23) for patients treated with LD regimen; 16+ 
      months (range 9-26) for responders versus 7 months (range 1-22) for 
      nonresponders. All these three variables (diagnosis, treatment, and response to 
      treatment) turned out to be statistically significant (p = at least less than 
      0.01) at Cox's analysis.
FAU - Maiolo, A T
AU  - Maiolo AT
AD  - Institute of Medical Sciences, University of Milan, Italy.
FAU - Cortelezzi, A
AU  - Cortelezzi A
FAU - Calori, R
AU  - Calori R
FAU - Polli, E E
AU  - Polli EE
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Recombinant Proteins)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Interferon-gamma/administration & dosage/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Myelodysplastic Syndromes/*drug therapy
MH  - Recombinant Proteins/administration & dosage/pharmacology/therapeutic use
MH  - Risk Factors
EDAT- 1990/07/01 00:00
MHDA- 1990/07/01 00:01
CRDT- 1990/07/01 00:00
PHST- 1990/07/01 00:00 [pubmed]
PHST- 1990/07/01 00:01 [medline]
PHST- 1990/07/01 00:00 [entrez]
PST - ppublish
SO  - Leukemia. 1990 Jul;4(7):480-5.